Patients with systemic lupus erythematosus (SLE) appear to have an increased risk of developin malignant tumours,1 2 particularly lymphomas.
Despite the hyperactivity of B lymphocytes seen in SLE, multiple myeloma seems to be uncommon, there being single reports only by Canoso and Cohen' and Jordan et al. 4 Two patients with SLE who developed extramedullary plasmacytomas have been described so far.5 6 We report a third case of SLE with multiple myeloma which was unusual in that there was widespread extramedullary involvement by undifferentiated plasma cells. This is a feature of the aggressive myeloma variant recently described in five patients by Suchman et al.7 and in two further patients by Foucar et Three months later she felt generally weak, and examination revealed crepitations at both lung bases which were attributed to pulmonary involvement by her lupus. Azathioprine 150 mg daily was therefore added. She remained well on reducing doses of prednisolone until December 1979, when azathioprine was stopped, but a month later she was admitted with severe malaise, pleurisy, arthralgia, and Raynaud's phenomenon. She then had alopecia and persisting bilateral pulmonary basal crepitations, a normal chest x-ray and blood urea, but increased 24-hour urinary protein (1-1 g) and hypocomplementaemia.
The dose of prednisolone was increased to 50 mg daily and azathioprine was reintroduced at 150 mg daily. She remained well on reducing doses of prednisolone until November 1980, when she again developed leucopenia (3-5 x 109/l). At this stage the DNA-binding activity was 980 U/ml and 24-hour urinary protein 1-3 g. Azathioprine was stopped and chlorambucil 2 mg daily substituted, but two months later she was readmitted with pleurisy, chest infection, myalgia, and mouth ulcers. On this occasion there was a Coombs-positive haemolytic anaemia and hypocomplementaemia. Chlorambucil was discontinued and prednisolone increased to 40 mg daily; two months later azathioprine 150 mg daily was reintroduced. In April 1981 she became severely depressed and weak: she was found to have a 653 proximal myopathy, hypertension (200/130 mmHg), and diabetes mellitus. In addition her creatinine clearance had fallen to 27 ml/minute, blood urea was 12-7 mmol/l, and 24-hour protein excretion was 4-4 g. Levels of DNA antibodies were still elevated at 620 U/ml. The blood pressure was controlled with hydralazine, while her diabetes and myopathy responded to a reduction of the steroid dose.
In June 1982 she developed a crush fracture of one thoracic vertebra. Serum protein electrophoresis, which had been normal seven months previously, now showed an IgG kappa paraprotein (10 g/l), but a skeletal survey showed no malignant deposits. Serum calcium was 2-3 mmol/l. A coin lesion was noted in the left mid-zone on chest x-ray, but bronchoscopy was normal and the lesion decreased in size spontaneously. Lung function tests showed a restrictive defect. She continued to take prednisolone 6 mg and azathioprine 100 mg daily as well as hydralazine, but in November 1982 developed malaise and weakness and was readmitted to hospital. There was proximal muscle weakness, hypertension, and tachycardia; the liver was enlarged 4 cm below the costal margin and was tender. The serum sodium was 129 mmol/l, potassium 5-5 mmol/l, and urea 13*6 mmol/l; repeated blood cultures were negative. The paraprotein concentration was 15 g/l, with IgA 3-8 g/l and IgM 1-9 g/l; Bence Jones protein was not detected. A bone scan was normal, and sternal bone marrow examination showed only 4% plasma cells; these were of normal morphology. DNA During the four years prior to the detection of the paraprotein this patient was treated with prednisolone in doses of between 6 and 60 mg daily, and for 40 months of this period with azathioprine as well at a daily dose of 100 mg or 150 mg (1-3-2 mg/kg). In view of the increased prevalence of tumours in other groups of immunosuppressed patientslt) the possibility that this drug treatment and the development of multiple myeloma are related has to be considered. In this context it is of interest that Neuberg5 reported a patient with an 11-year history of SLE who developed extramedullary plasmacytomas in a lymph node, the jaw, and the cervix over a four-year period during treatment with azathioprine.
Although a variety of tumours have been reported in patients with SLE,3 this is only the third report of a patient with multiple myeloma. The paraprotein was first detected in this case six months before death, some six years after the onset of SLE. It is possible that both the SLE and the myeloma result from an underlying defect in immunoregulation in these patients. Alternatively, impaired cellular immune function such as decreased suppressor cell activitylt and defective NK cell function,' 2 which are seen in SLE, or the immunosuppressive drugs used to treat the disease, may permit the emergence of a malignant clone of plasma cells.
In view of the many reports of lymphoproliferative disorders seen in SLE, the effect of immunosuppressive drugs on host defence mechanisms, such as anti-idiotypic regulation of B-cell neoplasms,13 needs urgent clarification.
